Class information for:
Level 1: GEFITINIB//EGFR MUTATION//ERLOTINIB

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
147 4147 40.3 88%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
6 4 GASTROENTEROLOGY & HEPATOLOGY//ONCOLOGY//SURGERY 1371034
216 3       NON SMALL CELL LUNG CANCER//LUNG CANCER//THORAC SURG 51214
1717 2             GEFITINIB//EGFR MUTATION//MIDKINE 6648
147 1                   GEFITINIB//EGFR MUTATION//ERLOTINIB 4147

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 GEFITINIB authKW 2216239 16% 45% 671
2 EGFR MUTATION authKW 1850181 9% 69% 365
3 ERLOTINIB authKW 1572933 13% 40% 536
4 NON SMALL CELL LUNG CANCER authKW 835784 25% 11% 1048
5 EGFR authKW 646384 17% 13% 690
6 AFATINIB authKW 638040 3% 66% 132
7 EGFR TKI authKW 498864 3% 56% 121
8 EPIDERMAL GROWTH FACTOR RECEPTOR authKW 451729 12% 13% 477
9 T790M authKW 438074 2% 86% 69
10 EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION authKW 395852 2% 67% 80

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class
1 Oncology 84482 73% 0% 3010
2 Respiratory System 24383 20% 0% 840
3 Pathology 2208 7% 0% 296
4 Pharmacology & Pharmacy 422 9% 0% 354
5 Medical Laboratory Technology 288 2% 0% 68
6 Medicine, Research & Experimental 203 4% 0% 159
7 Cell Biology 137 5% 0% 213
8 Medicine, General & Internal 84 4% 0% 162
9 Chemistry, Medicinal 23 2% 0% 63
10 Biotechnology & Applied Microbiology 15 2% 0% 101

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 GUANGDONG LUNG CANC 179698 2% 38% 65
2 THORAC ONCOL SERV 154540 2% 33% 64
3 LOWE THORAC ONCOL 140624 1% 33% 58
4 THORAC ONCOL 139860 5% 10% 199
5 MED ONCOL 73385 16% 1% 682
6 HEMATOL ONCOL P MED 52802 1% 21% 34
7 STATE SOUTH CHINA 46871 0% 58% 11
8 THORAC MED ONCOL 46560 1% 26% 24
9 THORAC SURG 40450 8% 2% 333
10 THORAC ONCOL SERV SOLID TUMOR ONCOL 36066 0% 70% 7

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 JOURNAL OF THORACIC ONCOLOGY 262701 7% 12% 309
2 LUNG CANCER 173513 8% 7% 323
3 CLINICAL LUNG CANCER 100729 2% 13% 102
4 THORACIC CANCER 21754 1% 8% 39
5 TARGETED ONCOLOGY 15986 1% 7% 30
6 CLINICAL CANCER RESEARCH 13961 4% 1% 169
7 ONCOTARGETS AND THERAPY 9947 1% 3% 51
8 JOURNAL OF CLINICAL ONCOLOGY 8842 3% 1% 141
9 LANCET ONCOLOGY 6365 1% 2% 40
10 REVUE DE PNEUMOLOGIE CLINIQUE 5425 1% 4% 21

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with term
in class		 LCSH search Wikipedia search
1 GEFITINIB 2216239 16% 45% 671 Search GEFITINIB Search GEFITINIB
2 EGFR MUTATION 1850181 9% 69% 365 Search EGFR+MUTATION Search EGFR+MUTATION
3 ERLOTINIB 1572933 13% 40% 536 Search ERLOTINIB Search ERLOTINIB
4 NON SMALL CELL LUNG CANCER 835784 25% 11% 1048 Search NON+SMALL+CELL+LUNG+CANCER Search NON+SMALL+CELL+LUNG+CANCER
5 EGFR 646384 17% 13% 690 Search EGFR Search EGFR
6 AFATINIB 638040 3% 66% 132 Search AFATINIB Search AFATINIB
7 EGFR TKI 498864 3% 56% 121 Search EGFR+TKI Search EGFR+TKI
8 EPIDERMAL GROWTH FACTOR RECEPTOR 451729 12% 13% 477 Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR
9 T790M 438074 2% 86% 69 Search T790M Search T790M
10 EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION 395852 2% 67% 80 Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR+MUTATION Search EPIDERMAL+GROWTH+FACTOR+RECEPTOR+MUTATION

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , THUNNISSEN, E , LADANYI, M , LINDEMAN, NI , CAGLE, PT , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS GUIDELINE FROM THE COLLEGE OF AMERICAN PATHOLOGISTS, INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, AND ASSOCIATION FOR MOLECULAR PATHOLOGY.JOURNAL OF THORACIC ONCOLOGY. VOL. 8. ISSUE 7. P. 823 -859 210 69% 228
2 LINDEMAN, NI , CAGLE, PT , BEASLEY, MB , CHITALE, DA , DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS GUIDELINE FROM THE COLLEGE OF AMERICAN PATHOLOGISTS, INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER, AND ASSOCIATION FOR MOLECULAR PATHOLOGY.JOURNAL OF MOLECULAR DIAGNOSTICS. VOL. 15. ISSUE 4. P. 415 -453 209 69% 139
3 LINDEMAN, NI , CAGLE, PT , BEASLEY, MB , CHITALE, DA , DACIC, S , GIACCONE, G , JENKINS, RB , KWIATKOWSKI, DJ , SALDIVAR, JS , SQUIRE, J , ET AL (2013) MOLECULAR TESTING GUIDELINE FOR SELECTION OF LUNG CANCER PATIENTS FOR EGFR AND ALK TYROSINE KINASE INHIBITORS.ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. VOL. 137. ISSUE 6. P. 828 -860 207 69% 138
4 MIDHA, A , DEARDEN, S , MCCORMACK, R , (2015) EGFR MUTATION INCIDENCE IN NON-SMALL-CELL LUNG CANCER OF ADENOCARCINOMA HISTOLOGY: A SYSTEMATIC REVIEW AND GLOBAL MAP BY ETHNICITY (MUTMAPII).AMERICAN JOURNAL OF CANCER RESEARCH. VOL. 5. ISSUE 9. P. 2892 -+ 133 78% 13
5 PAO, W , CHMIELECKI, J , (2010) RATIONAL, BIOLOGICALLY BASED TREATMENT OF EGFR-MUTANT NON-SMALL-CELL LUNG CANCER.NATURE REVIEWS CANCER. VOL. 10. ISSUE 11. P. 760-774 106 67% 403
6 SORIA, JC , MOK, TS , CAPPUZZO, F , JANNE, PA , (2012) EGFR-MUTATED ONCOGENE-ADDICTED NON-SMALL CELL LUNG CANCER: CURRENT TRENDS AND FUTURE PROSPECTS.CANCER TREATMENT REVIEWS. VOL. 38. ISSUE 5. P. 416 -430 112 77% 65
7 TAN, DSW , YOM, SS , TSAO, MS , PASS, HI , KELLY, K , PELED, N , YUNG, RC , WISTUBA, II , YATABE, Y , UNGER, M , ET AL (2016) THE INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER CONSENSUS STATEMENT ON OPTIMIZING MANAGEMENT OF EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER: STATUS IN 2016.JOURNAL OF THORACIC ONCOLOGY. VOL. 11. ISSUE 7. P. 946 -963 82 71% 9
8 CROSS, DAE , ASHTON, SE , GHIORGHIU, S , EBERLEIN, C , NEBHAN, CA , SPITZLER, PJ , ORME, JP , FINLAY, MRV , WARD, RA , MELLOR, MJ , ET AL (2014) AZD9291, AN IRREVERSIBLE EGFR TKI, OVERCOMES T790M-MEDIATED RESISTANCE TO EGFR INHIBITORS IN LUNG CANCER.CANCER DISCOVERY. VOL. 4. ISSUE 9. P. 1046 -1061 47 85% 209
9 RUSSO, A , FRANCHINA, T , RICCIARDI, GRR , PICONE, A , FERRARO, G , ZANGHI, M , TOSCANO, G , GIORDANO, A , ADAMO, V , (2015) A DECADE OF EGFR INHIBITION IN EGFR-MUTATED NON SMALL CELL LUNG CANCER (NSCLC): OLD SUCCESSES AND FUTURE PERSPECTIVES.ONCOTARGET. VOL. 6. ISSUE 29. P. 26814 -26825 76 80% 29
10 CHONG, CR , JANNE, PA , (2013) THE QUEST TO OVERCOME RESISTANCE TO EGFR-TARGETED THERAPIES IN CANCER.NATURE MEDICINE. VOL. 19. ISSUE 11. P. 1389 -1400 89 52% 220

Classes with closest relation at Level 1


Rank Class id link
1 5267 CRIZOTINIB//ANAPLASTIC LYMPHOMA KINASE//ALK
2 18265 VANDETANIB//NINTEDANIB//CEDIRANIB
3 4440 NIMOTUZUMAB//CETUXIMAB//EGFR
4 683 NON SMALL CELL LUNG CANCER//VINORELBINE//GEMCITABINE
5 16698 TRICHOMEGALY//EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS//SKIN TOXICITY
6 2234 PANITUMUMAB//CETUXIMAB//KRAS
7 15038 TTF 1//NAPSIN A//THYROID TRANSCRIPTION FACTOR 1
8 11421 ANILINOQUINAZOLINE//4 ANILINOQUINAZOLINE//VEGFR 2 INHIBITOR
9 13007 ERCC1//RRM1//MED OVARIAN CANC SECT
10 7694 LUNG CANCER//NEVER SMOKERS//HISTOLOGIC TYPE

Go to start page